Hypertension Center, Fuwai Hospital, State Key Laboratory of Cardiovascular Disease of China, National Center for Cardiovascular Diseases of China, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100037, China.
Department of Cardiology, Beijing ChaoYang Hospital, Capital Medical University, Beijing, 100020, China.
Microbiome. 2017 Feb 1;5(1):14. doi: 10.1186/s40168-016-0222-x.
Recently, the potential role of gut microbiome in metabolic diseases has been revealed, especially in cardiovascular diseases. Hypertension is one of the most prevalent cardiovascular diseases worldwide, yet whether gut microbiota dysbiosis participates in the development of hypertension remains largely unknown. To investigate this issue, we carried out comprehensive metagenomic and metabolomic analyses in a cohort of 41 healthy controls, 56 subjects with pre-hypertension, 99 individuals with primary hypertension, and performed fecal microbiota transplantation from patients to germ-free mice.
Compared to the healthy controls, we found dramatically decreased microbial richness and diversity, Prevotella-dominated gut enterotype, distinct metagenomic composition with reduced bacteria associated with healthy status and overgrowth of bacteria such as Prevotella and Klebsiella, and disease-linked microbial function in both pre-hypertensive and hypertensive populations. Unexpectedly, the microbiome characteristic in pre-hypertension group was quite similar to that in hypertension. The metabolism changes of host with pre-hypertension or hypertension were identified to be closely linked to gut microbiome dysbiosis. And a disease classifier based on microbiota and metabolites was constructed to discriminate pre-hypertensive and hypertensive individuals from controls accurately. Furthermore, by fecal transplantation from hypertensive human donors to germ-free mice, elevated blood pressure was observed to be transferrable through microbiota, and the direct influence of gut microbiota on blood pressure of the host was demonstrated.
Overall, our results describe a novel causal role of aberrant gut microbiota in contributing to the pathogenesis of hypertension. And the significance of early intervention for pre-hypertension was emphasized.
最近,肠道微生物群在代谢性疾病中的潜在作用,特别是在心血管疾病中的作用,已经被揭示出来。高血压是全球最常见的心血管疾病之一,但肠道微生物失调是否参与高血压的发生仍知之甚少。为了研究这个问题,我们在一个由 41 名健康对照者、56 名高血压前期患者、99 名原发性高血压患者组成的队列中进行了全面的宏基因组和代谢组学分析,并对患者进行了粪便微生物群移植到无菌小鼠。
与健康对照组相比,我们发现微生物丰富度和多样性明显降低,普雷沃氏菌主导的肠道肠型,与健康状态相关的细菌丰度降低,与疾病相关的功能改变,以及与疾病相关的微生物组成发生了明显变化,包括普雷沃氏菌和克雷伯氏菌的过度生长。出乎意料的是,高血压前期组的微生物特征与高血压组非常相似。高血压前期和高血压患者的宿主代谢变化与肠道微生物失调密切相关。我们构建了一个基于微生物群和代谢物的疾病分类器,可以准确地区分高血压前期和高血压患者与对照组。此外,通过将高血压患者的粪便移植到无菌小鼠中,我们观察到高血压可以通过微生物群转移,证明了肠道微生物群对宿主血压的直接影响。
总的来说,我们的研究结果描述了肠道微生物失调在高血压发病机制中的新的因果作用,并强调了对高血压前期进行早期干预的重要性。